Navigation Links
Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model

djuvants are not currently marketed for human use."

Dr. Fleury added, "Mymetics and its collaborators are the first group to report neutralizing IgA obtained after vaccination against HIV in non-human primates. In the coming year, Mymetics intends to conduct another study in non-human primates for testing of an improved vaccine version. Pending positive results, we may be able to file to initiate a clinical trial and begin phase I testing some time in late 2008."

Mymetics Vaccine Program Background

Worldwide, over 85 percent of HIV infections are the result of sexual transmission in which mucosal tissues from the genital and anorectal regions have been exposed to HIV-1 present in semen or secretions. According to a recent report from the International AIDS Vaccine Initiative, "Since an effective preventive AIDS vaccine will primarily have to protect an individual from sexual transmission of HIV, researchers think it will probably be important for a vaccine candidate to induce strong mucosal immune responses." Mymetics-affiliated researchers have been able to engineer gp41-derived antigens (proteins and peptides) capable of eliciting antibodies, particularly IgA antibodies, with strong potential for preventing in vitro virus translocation across the mucosal barrier and/or to inhibit cell infection, thus preventing HIV-1 infection.

    Mymetics has combined three important concepts in its vaccine design:


      1- Induction of mucosal and blood antibodies to allow protection in

      different anatomical compartments and block the early event of HIV

      translocation at the genito-reproductive and intestine tracts and

      subsequent infection of target cells underlying the mucosal tissues,

      thereby preventing HIV entry and spreading in the body.


      2- Focusing the immune response against conserved regions on gp41 that

      may induce protective antibodies against a broad range of HIV clades.

      Mymetics is develo
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
5. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
6. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
9. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
10. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
11. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
Post Your Comments:
(Date:10/22/2014)... Oct. 22, 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: ... its novel investigational drug for cancer, is designed for ... side effects. Its oncology focus is on melanoma, breast ... phase 2 trials of PV-10 as a therapy for ... for atopic dermatitis and psoriasis. This ...
(Date:10/22/2014)... NORWALK, Conn. , Oct. 22, 2014  Recently ... (GERD) have bolstered the already substantial database of evidence. ... and adoption of Stretta therapy for sufferers ... of clinical evidence supporting Stretta therapy as ... coverage policies that make Stretta therapy available to nearly ...
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014   ... and WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials ... Under the terms of the collaboration, Foundation Medicine will ... of Foundation Medicine,s FoundationOne® assay at the WuXi Genome ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5
... March 31, 2011 Navinta,s proprietary complex pharmaceutical ingredient, ... 7,179,939 and US Drug Master File is a key ... for Sodium Ferric Gluconate Complex in Sucrose Injection, 62.5 ... complex pharmaceutical ingredient technology provides a platform for preparation ...
... N.C., March 31, 2011 Paul Meade, the president ... NC company focused on facilitating medical expert collaborations with ... invitation to speak at the annual meeting of the ... 20th Annual Meeting and Clinical Congress of the American ...
Cached Medicine Technology:Paul Meade Accepts Invitation to Speak at AACE Annual Meeting 2
(Date:10/22/2014)... Va. (PRWEB) October 22, 2014 ... Innovation , which is dedicated to distribute health ... of healthcare delivery worldwide announced the development of ... which patients expect when receiving healthcare. These are ... for patient-centered care: “providing care that is respectful ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... CA (PRWEB) October 22, 2014 Lintelus, ... Cormier, Sr. Vice President of Sales, will be speaking ... upcoming Meetings Technology Expo on October 28, at the ... be hosting a booth as well as a Tech ... Lintelus Meeting can create a more engaging event experience. ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter , ... in vitro fertilization (IVF) are only about half as likely ... reproduction technique, new research indicates, and the racial disparity persists ... about 31 percent of white patients became pregnant after IVF, ... more than 4,000 IVF cycles over two years to tease ...
(Date:10/22/2014)... News) -- Measures taken by Firestone officials at the ... have limited the spread of the disease there and ... Natural Rubber Co. provides health services to about 80,000 ... populated communities. Between Aug. 1 and Sept. 23, ... those 80,000 people. That incidence rate of 0.09 percent ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... 6000(TM) and PulseOx 6100(TM) to be launched at MEDICA ... Medical Inc. (OTC,Bulletin Board: SPOM), a leading developer of ... today announced that,the PulseOx 6000(TM) and PulseOx 6100(TM), two ... at the 39th MEDICA World Forum for,Medicine in Dusseldorf, ...
... CHICAGO, Nov. 14 Health Care Service Corporation,(HCSC), ... plans in Illinois,New Mexico, Oklahoma and Texas, today ... Hemingway Hall as the company,s new president and,chief ... F. McCaskey,HCSC chief executive officer. Hemingway Hall ...
... Anthem Blue Cross and Blue, Shield provides funding to ... located in the eastern and western parts of the ... Cross and Blue,Shield today launched its new State Health ... and help address major health,issues in the state. Anthem ...
... - Parascript(R) AccuDetect(TM) to work with mammography systems ... to reduce industry problem of false-positives and ... -, BOULDER, Colo., Nov. 14 Parascript, ... today announced its,entrance into the medical imaging market. ...
... Sales Total $3.1 Million in Quarter; Amoxicillin PULSYS NDA ... Review Ongoing - PDUFA Date ... MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ), a pharmaceutical company ... and operational results for the quarter ended September,30, 2007. ...
... details CTI,s new cancer drug development platform, ... heard first-hand the progress and prospects of three ... and MTAX: CTIC) oncology drug,candidates, as well as ... this,year, from an international panel of clinical investigators ...
Cached Medicine News:Health News:SPO Medical Unveils New Oximetry Devices for European Markets 2Health News:SPO Medical Unveils New Oximetry Devices for European Markets 3Health News:Health Care Service Corporation Names New President and Chief Operating Officer 2Health News:Anthem Blue Cross and Blue Shield in Kentucky Announces Release of State Health Index 2Health News:Anthem Blue Cross and Blue Shield in Kentucky Announces Release of State Health Index 3Health News:Anthem Blue Cross and Blue Shield in Kentucky Announces Release of State Health Index 4Health News:Parascript Enters Medical Imaging Breast Cancer Detection Market With Established Image Analysis Technology 2Health News:MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results 2Health News:MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results 3Health News:MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results 4Health News:MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results 5Health News:MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results 6Health News:MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results 7Health News:MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results 8Health News:MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results 9Health News:MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results 10Health News:MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results 11Health News:MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results 12Health News:MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results 13Health News:MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results 14Health News:Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Drug Pipeline 2Health News:Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Drug Pipeline 3Health News:Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Drug Pipeline 4Health News:Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Drug Pipeline 5Health News:Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Drug Pipeline 6Health News:Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Drug Pipeline 7Health News:Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Drug Pipeline 8
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: